Jefferies Comments on Amarin (AMRN), Remains One of the Top Picks in Biotech
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Price: $14.09 +0.21%
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies is reaffirming its Buy rating and $25 price target on shares of Amarin Corporation (NASDAQ: AMRN) following the company's oral presentation of MARINE data.
The company reported that MARINE data at the European Society of Cardiology meeting. Positive top-line data with AMR101 has been previously announced by AMRN from the MARINE Phase 3 trial in patients with very high triglycerides. They also posted positive data at the National Lipid Association meeting in May and in a MARINE use patent application.
Amarin still plans to present LDL particle data in an oral presentation at the American Heart Association meeting in November. The firm notes that they remain optimistic about the overall clinical profile of AMR101 to date.
An analyst at the Jefferies comments, "We remain positive on AMR101 regulatory approval and continue to believe that the potential marketing message of no significant LDLC increases will resonate with all physicians and the LDL particle number and ApoB message will appeal to cardiologists in differentiating AMR101 from Lovaza."
Shares of AMRN remain one of the firms top biotech picks currently.
For more ratings news on Amarin Corporation click here and for the rating history of Amarin Corporation click here.
Shares of Amarin Corporation closed at $11.23 yesterday.
The company reported that MARINE data at the European Society of Cardiology meeting. Positive top-line data with AMR101 has been previously announced by AMRN from the MARINE Phase 3 trial in patients with very high triglycerides. They also posted positive data at the National Lipid Association meeting in May and in a MARINE use patent application.
Amarin still plans to present LDL particle data in an oral presentation at the American Heart Association meeting in November. The firm notes that they remain optimistic about the overall clinical profile of AMR101 to date.
An analyst at the Jefferies comments, "We remain positive on AMR101 regulatory approval and continue to believe that the potential marketing message of no significant LDLC increases will resonate with all physicians and the LDL particle number and ApoB message will appeal to cardiologists in differentiating AMR101 from Lovaza."
Shares of AMRN remain one of the firms top biotech picks currently.
For more ratings news on Amarin Corporation click here and for the rating history of Amarin Corporation click here.
Shares of Amarin Corporation closed at $11.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
